CVS Health (CVS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.58
- EPS estimate
- $1.85
- EPS surprise
- +39.14%
- Revenue surprise
- +6.07%
- Revenue
- $106.1B
- Revenue estimate
- $100.0B
- Reported
- Aug 5, 2026
CVS Health reported Q2 2026 results on August 5, 2026. Earnings per share were $2.58, ahead of the $1.85 estimate by 39.14%. Revenue was $106.1 billion, above the $100.0 billion consensus. Compared with Q2 2025, EPS rose about 42% from $1.81 and revenue rose about 7% from $98.9 billion.
Both figures are the highs in the table, and the beat was the largest in it. Annual EPS was $8.70 in 2022 and $8.74 in 2023, fell to $5.42 in 2024, then recovered to $6.75 in 2025. Revenue grew every year, from $322.4 billion in 2022 to $402.1 billion in 2025, up about 25%. The first half of 2026 adds up to $5.15 per share, about 27% more than a year earlier. Over the last 20 quarters, CVS Health topped the EPS estimate 18 times. The two misses both came in 2024: Q1, at 22.73% below, and Q3, at 24.09% below.
CVS Health reported Q3 results between October 29 and November 6 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether EPS stays above the levels of the same quarters in 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $1.85 | $2.58 | +39.14% | $106.1B | SEC |
| Q1 2026 | May 6, 2026 | $2.18 | $2.57 | +17.70% | $100.4B | SEC |
| Q4 2025 | Feb 10, 2026 | $1.00 | $1.09 | +8.72% | $105.7B | SEC |
| Q3 2025 | Oct 29, 2025 | $1.37 | $1.60 | +17.21% | $102.9B | SEC |
| Q2 2025 | Jul 31, 2025 | $1.46 | $1.81 | +24.14% | $98.9B | SEC |
| Q1 2025 | May 1, 2025 | $1.70 | $2.25 | +32.15% | $94.6B | SEC |
| Q4 2024 | Feb 12, 2025 | $0.91 | $1.19 | +30.25% | $97.7B | SEC |
| Q3 2024 | Nov 6, 2024 | $1.44 | $1.09 | −24.09% | $95.4B | SEC |
| Q2 2024 | Aug 7, 2024 | $1.74 | $1.83 | +5.31% | $91.2B | SEC |
| Q1 2024 | May 1, 2024 | $1.70 | $1.31 | −22.73% | $88.4B | SEC |
| Q4 2023 | Feb 7, 2024 | $1.99 | $2.12 | +6.50% | $93.8B | SEC |
| Q3 2023 | Nov 1, 2023 | $2.13 | $2.21 | +3.67% | $89.8B | SEC |
| Q2 2023 | Aug 2, 2023 | $2.12 | $2.21 | +4.43% | $88.9B | SEC |
| Q1 2023 | May 3, 2023 | $2.10 | $2.20 | +4.59% | $85.3B | SEC |
| Q4 2022 | Feb 8, 2023 | $1.92 | $1.99 | +3.53% | $83.8B | SEC |
| Q3 2022 | Nov 2, 2022 | $2.00 | $2.09 | +4.69% | $81.2B | SEC |
| Q2 2022 | Aug 3, 2022 | $2.18 | $2.40 | +10.06% | $80.6B | SEC |
| Q1 2022 | May 4, 2022 | $2.17 | $2.22 | +2.48% | $76.8B | SEC |
| Q4 2021 | Feb 9, 2022 | $1.85 | $1.98 | +7.30% | $76.6B | SEC |
| Q3 2021 | Nov 3, 2021 | $1.79 | $1.97 | +10.34% | $73.8B | SEC |
Quarterly revenue
Frequently asked questions
When did CVS Health (CVS) last report earnings?
CVS Health last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did CVS beat earnings estimates?
Yes. CVS Health reported EPS of $2.58 for Q2 2026 against a $1.85 estimate — a 39.14% beat.
How much revenue did CVS report last quarter?
CVS Health reported $106.1B in revenue for Q2 2026, against a consensus estimate of $100.0B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.